Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
Teva药品在欧洲神经学会大会上展示了PEARL偏头痛预防研究的第4次中期分析；新的亚分析突出了治疗暂停对患者结果的潜在负面影响
- 4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki
- New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes1
- Sub-analysis exploring impact of treatment cessation and reinitiation on migraine prevention suggests potential rise in migraine attacks and diminished treatment effectiveness upon reinitiation1
- PEARL实际世界偏头痛预防研究的第4次中期分析在赫尔辛基举行的第10届欧洲神经学协会（EAN）大会上展示。
- PEARL数据的新子分析突出了治疗暂停对患者结果的潜在负面影响1。
- 探讨治疗停止和重新开始对偏头痛预防的影响的子分析表明，在重新开始后可能会出现偏头痛发作和治疗效果降低1。